NDA 020727 · Azurity
Bidil
Hydralazine Hydrochloride, Isosorbide Dinitrate · Oral · Nitrate Vasodilator
Last checked: Nov 20, 2026Latest source record: Jan 13, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jun 23, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
63
14 Phase 3, 4 recruiting
FAERS reports
429
303 serious, 66 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 30, 2025.
BiDil is a combination of isosorbide dinitrate, a nitrate vasodilator, and hydralazine hydrochloride, an arteriolar vasodilator, indicated for: the treatment of heart failure as an adjunct therapy to standard therapy in self-identified black patients to improve survival, prolong time to hospitalization for heart failure and to improve patient-reported functional status ( 1.1 ) Limitations of use: There is little experience in patients with NYHA class IV heart failure ( 1.2 ) 1.1 Treatment of Heart Failure in Self-identified Black Patients BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. 1.2 Limitations of Use There is little experience in patients with NYHA class IV heart failure.
Mechanism: The mechanism of action underlying the beneficial effects of BiDil in the treatment of heart failure has not been established. Isosorbide dinitrate is a vasodilator affecting both arteries and veins. Its dilator properties result from the release of nitric oxide and the subsequent activation of guanylyl cyclase, and ultimate relaxation of vascular smooth muscle. Several well-controlled clinical trials have used exercise testing to assess the anti-anginal efficacy of chronically-delivered nitrates. In the large majority of these trials, active agents were no more effective than placebo after...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BIDIL · HYDRALAZINE HYDROCHLORIDE 37.5MG; ISOSORBIDE DINITRATE 20MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydralazine" as an intervention, any sponsor and status, largest first.
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- DANHEART (H-HeFT and Met-HeFT)Pivotal-lookingCompleted
Henrik WiggersAcademic, hospital or other
NCT03514108 · 1,100 participants · Start Mar 1, 2018 · Primary completion Dec 31, 2025
Drug: Hydralazine Isosorbide Dinitrate; Placebo Oral Tablet and 2 more · For: Heart Failure; Diabetes
Sites: Holbæk, Denmark; Aabenraa, Denmark; Aalborg, Denmark · 26 sites in all
- African-American Heart Failure TrialPivotal-lookingCompleted
NitromedIndustry
NCT00047775 · 1,100 participants · Start May 2001
Drug: BiDil · For: Congestive Heart Failure
Sites: Birmingham, Alabama; Little Rock, Arkansas; Washington D.C., District of Columbia · 7 sites in all
- Baroreflex Activation Therapy for Heart FailurePivotal-lookingCompleted
CVRx, Inc.Industry
NCT02627196 · 1,090 participants · Start Apr 19, 2016 · Primary completion Oct 2023
Drug: Medical Management · For: Heart Failure
Sites: Chandler, Arizona; Mesa, Arizona; Phoenix, Arizona · 92 sites in all
- Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation StudyPivotal-lookingCompleted
University Hospital, Basel, SwitzerlandAcademic, hospital or other
NCT00512759 · 781 participants · Start Dec 10, 2007 · Primary completion Aug 24, 2018
Drug: Goal-directed preload and afterload decrement · For: Acute Heart Failure
Sites: São Paulo, Brazil; Sofia, Bulgaria; Mainz, Germany · 12 sites in all
- HALT Progression of Polycystic Kidney Disease Study APivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00283686 · 558 participants · Start Jan 2006 · Primary completion Jun 2014
Drug: Lisinopril; Telmisartan and 1 more · For: Kidney, Polycystic
Sites: Aurora, Colorado; Atlanta, Georgia; Kansas City, Kansas · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- renal failure54
- chronic kidney disease51
- acute kidney injury42
- cardiac failure congestive42
- nausea38
- dyspnoea37
- fatigue35
- diarrhoea33
- end stage renal disease29
- headache28
- dizziness27
- pain27
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 8 |
| 2007 | 1 |
| 2008 | 7 |
| 2009 | 8 |
| 2010 | 11 |
| 2011 | 15 |
| 2012 | 21 |
| 2013 | 9 |
| 2014 | 33 |
| 2015 | 31 |
| 2016 | 35 |
| 2017 | 55 |
| 2018 | 38 |
| 2019 | 53 |
| 2020 | 40 |
| 2021 | 22 |
| 2022 | 13 |
| 2023 | 15 |
| 2024 | 7 |
| 2025 | 2 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bidil (Isosorbide Dinit/Hydralazine)
2024 spending
$520K
Beneficiaries
301
923 claims
Per beneficiary
$1,726
$4.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,586,874 |
| 2021 | $13,915,297 |
| 2022 | $8,826,644 |
| 2023 | $1,632,501 |
| 2024 | $519,595 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.
Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. · JACC Heart Fail 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Guidelines-similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension.
Scott G, Gillon TE, Pels A, et al. · Am J Obstet Gynecol 2022 · Systematic Review
- Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial.
S D, Novri DA, Hamidy Y, et al. · F1000Res 2022 · Randomized Controlled Trial
- Heart failure.
McKelvie RS · BMJ Clin Evid 2011 · Systematic Review
- Heart failure.
McKelvie RS · BMJ Clin Evid 2010 · Systematic Review
- Hydralazine for essential hypertension.
Kandler MR, Mah GT, Tejani AM, et al. · Cochrane Database Syst Rev 2011 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.